Table 2.
Study cohort description at baseline (N = 53).
| Variable | Mean (SD) or N (%) | Range | N (%) Missing |
|---|---|---|---|
| Age (years) | 34.7 (4.45) | 23.0–46.0 | 0 (0%) |
| Female sex | 6 (11.3%) | 0 (0%) | |
| Education (years) | 11.3 (1.91) | 7.0–17.0 | 0 (0%) |
| Log10 HIV VL | 4.38 [4.08, 4.61] | 2.70–4.98 | 0 (0%) |
| HIV VL ≤ 500 | 12 (22.6%) | 0 (0%) | |
| CD4 Count | 272 (154) | 40–654 | 21 (39.6%) |
| HBV | 1 (1.9%) | 1 (1.9%) | |
| HCV | 49 (96.1%) | 2 (3.8%) | |
| Syphilis | 1 (1.9%) | 1 (1.9%) | |
| WBC | 6.00 [4.50, 7.69] | 2.90–49.00 | 2 (3.8%) |
| RBC | 4.60 [4.34, 5.00] | 3.26–14.30 | 2 (3.8%) |
| HGB | 140 [132, 153] | 17–167 | 2 (3.8%) |
| PLT | 173 [143, 249] | 14–350 | 3 (5.7%) |
| LYM | 31.1 [19.5, 41.3] | 1.2–56.5 | 3 (5.7%) |
| MON | 4.62 [3.48, 5.90] | 0.32–378.00 | 9 (17%) |
| RDW | 12.3 [11.2, 13.7] | 4.8–47.2 | 5 (9.4%) |
| MPV | 7.70 [6.50, 8.94] | 4.30–19.90 | 6 (11.3%) |
| Total Protein | 77.1 [71.1, 82.2] | 55.9–103.7 | 3 (5.7%) |
| Total Bilirubin | 8.40 [5.53, 13.70] | 1.80–55.90 | 3 (5.7%) |
| Direct Bilirubin | 6.25 [3.17, 8.65] | 1.10–10.60 | 47 (88.7%) |
| Cholesterol | 3.30 [2.90, 4.10] | 2.10–4.70 | 24 (45.3%) |
| AST | 43.7 [24.5, 64.5] | 4.3–309.0 | 2 (3.8%) |
| ALT | 37.8 [21.5, 61.1] | 5.7–160.0 | 3 (5.7%) |
| Glucose | 5.04 [4.48, 5.50] | 2.82–7.30 | 5 (9.4%) |
| Marijuana Utox+ | 0 (0%) | 0 (0%) | |
| Cocaine Utox+ | 0 (0%) | 0 (0%) | |
| Morphine Utox+ | 40 (75.5%) | 0 (0%) | |
| Methadone Utox+ | 40 (75.5%) | 0 (0%) | |
| Methamphetamine Utox+ | 0 (0%) | 0 (0%) | |
| Amphetamine Utox+ | 0 (0%) | 0 (0%) |
HBV = hepatitis B virus; HCV = hepatitis C virus; WBC = white blood cell; RBC = red blood cell; HGB = hemoglobin; PLT = platelet; LYM = lymphocyte; MON = monocyte; RDW = red cell distribution width; MPV = mean platelet volume; AST = aspartate aminotransferase; ALT = alanine transaminase; Utox = urine drug screen.